These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Aducanumab: Appropriate Use Recommendations Update. Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993 [TBL] [Abstract][Full Text] [Related]
11. Aducanumab: The first targeted Alzheimer's therapy. Yang P; Sun F Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067 [TBL] [Abstract][Full Text] [Related]
12. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329 [TBL] [Abstract][Full Text] [Related]
20. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]